Mark Altmeyer - Net Worth and Insider Trading
Mark Altmeyer Net Worth
The estimated net worth of Mark Altmeyer is at least $94,547 dollars as of 2023-03-30. Mark Altmeyer is the Director of Myovant Sciences Ltd and owns about 3,500 shares of Myovant Sciences Ltd (MYOV) stock worth over $94,430. Mark Altmeyer is also the Pres&Chief Commercial Officer of Sio Gene Therapies Inc and owns about 288 shares of Sio Gene Therapies Inc (SIOX) stock worth over $117. Details can be seen in Mark Altmeyer's Latest Holdings Summary section.
Transaction Summary of Mark Altmeyer
Mark Altmeyer Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Altmeyer owns 2 companies in total, including Myovant Sciences Ltd (MYOV) , and Sio Gene Therapies Inc (SIOX) .
Click here to see the complete history of Mark Altmeyer’s form 4 insider trades.
Insider Ownership Summary of Mark Altmeyer
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MYOV | Myovant Sciences Ltd | 2016-10-26 | director |
| SIOX | Sio Gene Therapies Inc | 2015-06-10 | Pres&Chief Commercial Officer |
Mark Altmeyer Latest Holdings Summary
Mark Altmeyer currently owns a total of 2 stocks. Among these stocks, Mark Altmeyer owns 3,500 shares of Myovant Sciences Ltd (MYOV) as of November 17, 2017, with a value of $94,430 and a weighting of 99.88%. Mark Altmeyer also owns 288 shares of Sio Gene Therapies Inc (SIOX) as of March 10, 2016, with a value of $117 and a weighting of 0.12%.
Latest Holdings of Mark Altmeyer
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MYOV | Myovant Sciences Ltd | 2017-11-17 | 3,500 | 26.98 | 94,430 |
| SIOX | Sio Gene Therapies Inc | 2016-03-10 | 288 | 0.41 | 117 |
Holding Weightings of Mark Altmeyer
Mark Altmeyer Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Altmeyer has made a total of 0 transactions in Myovant Sciences Ltd (MYOV) over the past 5 years. The most-recent trade in Myovant Sciences Ltd is the acquisition of 3,500 shares on November 17, 2017, which cost Mark Altmeyer around $46,830.
According to the SEC Form 4 filings, Mark Altmeyer has made a total of 0 transactions in Sio Gene Therapies Inc (SIOX) over the past 5 years. The most-recent trade in Sio Gene Therapies Inc is the acquisition of 288 shares on March 10, 2016, which cost Mark Altmeyer around $25,622.
Insider Trading History of Mark Altmeyer
- 1
Mark Altmeyer Trading Performance
GuruFocus tracks the stock performance after each of Mark Altmeyer's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Altmeyer is 23.07%. GuruFocus also compares Mark Altmeyer's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Altmeyer within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Altmeyer's insider trading performs compared to the benchmark.
Performance of Mark Altmeyer
Average Relative Return
35.03%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | -2.46 | 23.07 | 49.74 | 35.03 | -46.47 | -16.5 |
| Relative Return to S&P 500(%) | -5.8 | 17.42 | 43.52 | 22.35 | -60.67 | -28.09 |
Mark Altmeyer Ownership Network
Ownership Network List of Mark Altmeyer
Ownership Network Relation of Mark Altmeyer
Mark Altmeyer Owned Company Details
What does Myovant Sciences Ltd do?
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Who are the key executives at Myovant Sciences Ltd?
Mark Altmeyer is the director of Myovant Sciences Ltd. Other key executives at Myovant Sciences Ltd include Principal Financial Officer Uneek Mehra , Chief Commercial Officer Lauren Merendino , and director & Principal Executive Officer David C Marek .
Myovant Sciences Ltd (MYOV) Insider Trades Summary
Over the past 18 months, Mark Altmeyer made no insider transaction in Myovant Sciences Ltd (MYOV). Other recent insider transactions involving Myovant Sciences Ltd (MYOV) include a net sale of 28,515 shares made by Ferreira Juan Camilo Arjona , a net sale of 68,098 shares made by Matthew Lang , and a net sale of 74,833 shares made by David C Marek .
In summary, during the past 3 months, insiders sold 17,456 shares of Myovant Sciences Ltd (MYOV) in total and bought 51,599,200 shares, with a net purchase of 51,581,744 shares. During the past 18 months, 195,394 shares of Myovant Sciences Ltd (MYOV) were sold and 51,599,200 shares were bought by its insiders, resulting in a net purchase of 51,403,806 shares.
Myovant Sciences Ltd (MYOV)'s detailed insider trading history can be found in Insider Trading Tracker table.
Myovant Sciences Ltd Insider Transactions
Mark Altmeyer Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Altmeyer. You might contact Mark Altmeyer via mailing address: C/o Axovant Sciences, Inc., 1441 Broadway, 3rd Floor, New York Ny 10018.
